A fixed combination of 2 drugs in one pill.
Sold as Adderall, Mydayis.
A combination is graded by its riskiest ingredient: each part of the score is the lowest of the ingredients' scores. This grade answers one narrow question: how strong is the public evidence and safety record behind this drug, and how clean is its money trail and court record? It is not a verdict on whether the drug is right for you.
Each ingredient has its own full page with the FDA label, side-effect reports, recalls, evidence, and payments. Open them for the detail behind this grade.
Score breakdown (59/100)
Safety ×35%
F
Evidence ×25%
F
Regulatory ×15%
C
Money & lawsuits ×15%
B
Options ×10%
A
Safety: 48
Graded by its riskiest ingredient, amphetamine (48)
Carries an FDA boxed warning, the strongest warning the FDA issues (-30)
Federally controlled substance: dependence and misuse risk (-10)
Death appears in 4.6x the share of reports seen across all of FAERS (-12)
Evidence: 33
Graded by its riskiest ingredient, dextroamphetamine (33)
66 randomized trials and 0 systematic reviews/meta-analyses indexed in PubMed
No Cochrane review found (-5)
'Drug ineffective' is the single most-reported item about this drug in FAERS (-5)
Regulatory history: 74
Graded by its riskiest ingredient, dextroamphetamine (74)
Recalls since 2016: 1 Class I, 1 Class II, 0 Class III across 30 generic makers (-18)
8 label changes approved since 2021: the safety story is still moving (-8)
Money & lawsuits: 85
Graded by its riskiest ingredient, dextroamphetamine (85)
Pharma paid doctors $507,930 tied to this drug last year (-15)
Not named in any pending federal MDL
Options: 100
Graded by its riskiest ingredient, amphetamine (100)
Generic versions approved (19 applications)
12 same-class alternatives exist
Money and lawsuits
In 2024, drug companies reported $0 in payments to US physicians and hospitals tied to this combination's brands across 0 transactions.
No pending federal MDL names this combination or its brands.
The ingredients' own payments and lawsuits are on their pages and already count toward this grade.
Who takes it and what it costs
369,620Medicare Part D patients (2024)
2,508,114prescriptions filled
$45average cost per fill
$112Mtotal Medicare spend
Product
Fills
$/fill
Dextroamphetamine-Amphetamine
1,740,464
$29
Dextroamphetamine-Amphet ER
710,833
$54
Adderall XR
39,181
$309
Adderall
13,734
$663
Mydayis
3,902
$340
Questions to ask your prescriber
This is a fixed combination of amphetamine and dextroamphetamine. Why both together, instead of only the one I need?
This drug carries a boxed warning. Which specific risk does it cover, and does it apply to me?
This is a controlled substance. What is the plan for how long I take it and how I stop?
The most-reported problems in FDA's adverse event data are toxicity to various agents, drug abuse, completed suicide, overdose. How would we recognize and handle those?
Why this one over armodafinil, atomoxetine, dexmethylphenidate? What would make you pick one of those instead?
What result are we expecting, by when, and what is the plan if it does not happen?
If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)
The most-reported problems in FDA's adverse event data are fatigue, anxiety, nausea. How would we recognize and handle those?
Why this one over amphetamine, armodafinil, atomoxetine? What would make you pick one of those instead?